Logo for FT News podcast

Valeant said on Monday that chief executive Mike Pearson would be stepping down. The Canadian drugmaker also traded blame with its former chief financial officer over providing incorrect information to the company’s auditors that it said led to the filing of erroneous reports with the US securities regulator. The FT's David Crow and Sujeet Indap discuss the company's future.

Get alerts on when a new story is published

Copyright The Financial Times Limited 2018. All rights reserved.

Comments have not been enabled for this podcast.

Follow the topics in this podcast